While the supply of Moderna's COVID-19 vaccine is being disrupted due to problems in the overseas production process, Song Young-gil, chairman of the Democratic Party of Korea, said in a radio interview on the morning of the 28th that Moderna's vaccine will deliver 1.4 million doses next week and 8.5 million doses in August. It was announced that it was planned.



The Central Disaster and Safety Countermeasures Headquarters, which oversees the introduction of vaccines, said that it could not reveal the specific quantity until confirmed based on the confidentiality clause with pharmaceutical companies, but the representative of the ruling party has disclosed the quantity of vaccines currently under working-level discussion to the outside.



In a radio interview, CEO Song said, "A problem occurred during the (Modena) production process and as a result of quality control, shipments could not be made, so 750,000 servings on the 25th and 1.21 million to 1.96 million servings on the 31st were postponed. It was said that 1.3 million to 1.4 million servings will be provided. It is said that 8.5 million servings in August will arrive as scheduled."



However, in the briefing of the major script that was held after this interview, it was said that it is difficult to reveal the specific amount at the moment because additional working-level discussions are in progress.



Since the purchase of vaccines is a confidentiality agreement between the pharmaceutical company and the government, the specific supply volume and schedule cannot be disclosed until the vaccine is shipped, so CEO Song's remarks may constitute a breach of confidentiality.



In fact, the major script also said, "It is judged that the remarks of CEO Song fall under a confidentiality agreement, and a penalty is also possible."



He added, "I am somewhat sorry and apologetic that an inaccurate part was released through a different route."



Earlier in May, Minister of the Interior and Safety Jeon Jeon-cheol, during an interview with a daily newspaper, specifically disclosed the quantity of vaccines to be introduced by type, but was embroiled in a controversy over confidentiality violations.



Penalties for breach of confidentiality may result in pharmaceutical companies rescheduling, rescheduling, or even discontinuing supply altogether.



(Photo = Yonhap News)